Figure 7.

Progression-free survival and gene expression profile of EZB lymphomas acquiring N-glycosylation sites in the CDR. (A-B) Progression-free survival (PFS) was determined by the Kaplan-Meier method using log-rank statistics. The number of patients at risk is indicated in blue (CDR^–) or in red (CDR⁺) at each time point (years). (A) PFS in EZB GCB-DLBCL with N-glycosylation sites acquired in the CDR of the tumor Ig (CDR⁺) or not (CDR^–). (B) PFS in CDR⁺ and CDR^– EZB GCB-DLBCL without MYC translocation (EZB MYC^–). (C-D) Differential gene expression and BCR gene set enrichment in CDR⁺ compared with CDR^– EZB MYC^– DLBCL. (C) Each point represents a gene and the fold change and P value for differential expression in CDR⁺ vs CDR^– EZB MYC^– DLBCL. CDR⁺ had higher expression of positive log₂ fold changes, and CDR^– had higher expression of negative log₂ fold changes. Gray points were not differentially expressed genes. Light blue and magenta points were differentially expressed at P = .05, whereas blue and red points were differentially expressed at false discovery rate of 0.05 after controlling for multiple testing (Benjamini-Hochberg procedure). (D) Gene set enrichment analysis (GSEA) plot showing the enrichment of BCR signaling pathway genes in the log₂ fold change ranked genes for CDR⁺ vs CDR^–. Enrichment of the BCR pathway toward the beginning of the ranked list indicated that the BCR pathway was enriched in genes more highly expressed in CDR⁺ than in CDR^– EZB MYC^–. Leading-edge genes (ie, those observed on the left edge of the green curve) in the BCR pathway are listed in the same order as they appear on the x-axis.